Abstract
Lewis lung carcinoma (3LL) cells were constitutively resistant to Fas-mediated apoptosis, but overexpression of Fas on 3LL cells allowed Fas-mediated apoptosis after crosslinking with agonist anti-Fas antibody (Jo2) in vitro. Surprisingly, Fas-overexpressing 3LL cells showed enhanced in vivo tumor progression, whereas no promotion of in vivo tumor growth was observed for dominant negative (DN) Fas-overexpressing 3LL transfectants in which the cytoplasmic death domain was deleted. In addition, the promotion of in vivo tumor growth by Fas-overexpression was reduced in gld (FasL-mutation) mice compared to normal mice. These data indicate that intact Fas/FasL cell signaling is required for the promotion of in vivo tumor growth by Fas overexpression in 3LL cells. In contrast to the efficient Fas-mediated killing induced in vitro by crosslinking with anti-Fas antibody, Fas-overexpressing 3LL cells were resistant in vitro to Fas-mediated apoptosis by activated T cells or transient FasL transfection. These data suggest that agonist anti-Fas antibody and natural FasL can transmit qualitatively different signals, and crosslinking of Fas with natural FasL on 3LL cells does not deliver the expected death signal. Thus, our results demonstrate that in some cases overexpression of Fas can result in a survival advantage for tumor cells in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449–1456.
Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365.
Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11: 294–300.
Cohen PL, Eisenberg RA. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243–269.
Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39–43.
Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56: 4791–4798.
O’Connell J, O’Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075–1082.
Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994; 54: 1580–1586.
Plumas J, Jacob M-C, Chaperot L, Molens J-P, Sotto J-J, Bensa J-C. Tumor B cells from Non-Hodgkin’s lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998; 91: 2875–2885.
Mapara MY, Bargou R, Zugck C, et al. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl-2 oncogene expression. Eur J Immunol 1993; 23: 702–708.
Aggarwal BB, Singh S, Lapushin R, Totpal K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 1995; 364: 5–8.
Freiberg RA, Spencer DM, Choate KA, et al. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 1997; 108: 215–219.
Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178: 2231–2235.
Desbarats J, Wade T, Wade WF, Newell MK. Dichotomy between naïve and memory CD4+ T cells responses to Fas engagement. Proc Natl Acad Sci USA 1999; 96: 8104–8109.
Suzuki I, Fink PJ. The dual functions of Fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proc Natl Acad Sci USA 2000; 97: 1707–1712.
Suzuki I, Martin S, Boursalian TE, Beers C, Fink PJ. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. J Immunol 2000; 165: 5537–5543.
Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6: 920–923
Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/MORT1. Nature 1998; 392: 296–300.
Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–1462.
Trauth BC, Klas C, Peters AMJ, et al. Monoclonal antibodymediated tumor regression by induction of apoptosis. Science 1989; 245: 301–305.
Yoshida Y, Anzai N, Kawabata H. Apoptosis in normal and neoplastic hematopoiesis. Crit Rev Oncol Hematol 1996; 24: 185–211.
Lee J-K, Sayers TJ, Brooks AD, et al. IFN-?-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 2000; 164: 231–239.
Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996; 88: 38–43.
Wiltrout RH, Taramelli D, Holden HT. Measurement of macrophage-mediated cytotoxicity against adherent and nonadherent target cells by release of 111Indium-oxine. J Immunol Methods 1981; 43: 319–331.
Kayagaki N, Yamaguchi N, Nagao F, et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 1997; 94: 3914–3919.
Sayers TJ, Brooks AD, Lee J-K, et al. Molecular mechanisms of immune-mediated lysis of murine renal cancer: Differential contribution of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J Immunol 1998; 161: 3957–3965.
Thilenius ARB, Braun K, Russell JH. Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Eur J Immunol 1997; 27: 1108–1114.
Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler HG. Expression and function of CD95 (Fas/APO-1) in leukaemia-lymphoma tumor lines. J Haematol 1997; 96: 584–593.
Karawajew L, Wuchter C, Ruppert V, et al. ifferential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia 1997; 11: 1245–1252.
Westendorf JJ, Lammert JM, Jelinek DF. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995; 85: 3566–3576.
Fellenberg J, Mau H, Scheuerpflug C, Ewerbeck V, Debatin KM. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Int J Cancer 1997; 72: 536–542.
Weller M, Frei K, Groscurth P, Kran PH, Yon Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: Induction and modulation of sensitivity by cytokines. J Clin Invest 1994; 94: 954–964.
Watanabe-Fukunaga R, Brannan CI, Itoh N, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274–1279.
Fadeel B, Thorpe CJ, Yonehara S, Chiodi F. Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro. Int Immunol 1997; 9: 201–209.
Biancone L, Martino AD, Orlandi V, Conaldi PG, Toniolo A, Camussi G. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med 1997; 186: 147–152.
Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regualted kinase activation. Cancer Res 2000; 60: 1766–1772.
Zornig M, Hueber A-O, Evan G. p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol 1998; 8: 467–470.